| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | NEUTRAL | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.16▲ | 1.17▼ | 1.17▼ | 1.10▲ | 1.18▼ |
| MA10 | 1.16▲ | 1.18▼ | 1.17▼ | 1.09▲ | 1.14▲ |
| MA20 | 1.18▼ | 1.15▲ | 1.13▲ | 1.14▲ | 1.27▼ |
| MA50 | 1.16▲ | 1.09▲ | 1.09▲ | 1.10▲ | 1.78▼ |
| MA100 | 1.11▲ | 1.08▲ | 1.16▲ | 1.32▼ | 2.69▼ |
| MA200 | 1.09▲ | 1.19▼ | 1.10▲ | 1.79▼ | 20.67▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | -0.003▼ | 0.003▲ | 0.003▲ | 0.031▲ |
| RSI | 50.971▲ | 60.906▲ | 61.316▲ | 52.410▲ | 44.212▼ |
| STOCH | 40.278 | 23.651 | 47.862 | 47.610 | 30.993 |
| WILL %R | -62.500 | -57.143 | -41.379 | -72.086 | -67.460 |
| CCI | 11.855 | -40.230 | 25.888 | 37.101 | -14.480 |
|
Thursday, March 05, 2026 01:38 PM
Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings and Warrant Exercises Strengthen Balance ...
|
|
Thursday, March 05, 2026 01:29 PM
Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings and Warrant Exercises Strengthen Balance ...
|
|
Monday, February 23, 2026 03:48 PM
Phase 1b Trial Reported Approximately 65% Pathological Response in cSCC, Including Complete Responses at Maximum Dose, ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 06/03/26 | 1.17 | 1.23 | 1.15 | 1.16 | 328,399 |
| 05/03/26 | 1.16 | 1.215 | 1.15 | 1.17 | 659,959 |
| 04/03/26 | 1.05 | 1.15 | 1.04 | 1.15 | 861,325 |
| 03/03/26 | 1.00 | 1.05 | 0.978 | 1.01 | 462,096 |
| 02/03/26 | 1.07 | 1.0775 | 1.01 | 1.02 | 638,323 |
| 27/02/26 | 1.06 | 1.16 | 1.06 | 1.14 | 550,346 |
| 26/02/26 | 1.06 | 1.105 | 1.03 | 1.07 | 300,928 |
| 25/02/26 | 1.09 | 1.12 | 1.05 | 1.05 | 474,055 |
| 24/02/26 | 1.04 | 1.12 | 1.01 | 1.08 | 769,724 |
| 23/02/26 | 1.03 | 1.06 | 1.00 | 1.02 | 0 |
|
|
||||
|
|
||||
|
|